KR930002327A - 치환된 시클로프로필아미노-1, 3, 5-트리아진 - Google Patents
치환된 시클로프로필아미노-1, 3, 5-트리아진 Download PDFInfo
- Publication number
- KR930002327A KR930002327A KR1019920013231A KR920013231A KR930002327A KR 930002327 A KR930002327 A KR 930002327A KR 1019920013231 A KR1019920013231 A KR 1019920013231A KR 920013231 A KR920013231 A KR 920013231A KR 930002327 A KR930002327 A KR 930002327A
- Authority
- KR
- South Korea
- Prior art keywords
- cyclopropylamino
- triazine
- thiomorpholino
- formula
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Resins (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 하기 일반식(I)의 화합물의 광학활성 이성질체 및 라세미 혼합물을 포함하여 치환된 시클로프로필아미노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.상기 식에서, R1은 1 내지 3개의 탄소원자를 가지는 알킬 라디칼, 비치환 시클로알킬 라디칼 또는 최소한 하나의 알킬 라디칼로 치환된, 3 내지 5개의 탄소원자를 가지는 시클로알킬 라디칼을 나타내며, R2는 비스(2-히드록시에틸)아미노, 3-히드록시-1-아제티디닐, 3-메톡시-1-아제티디닐, 3-옥소-1-아제티디닐, 모르폴리노, 4-히드록시피페리디노, 티오모르폴리노, 티오모르폴리노 S-옥사이드, 티오모르폴리노 S,S-디옥시드, 3-티아졸리디닐, 3-티아졸리디닐 S-옥사이드, 3-티아졸리디닐 S,S-디옥시드 또는 8-옥사-아자비시클로[3,2,1]옥트-3-일 라디칼을 나타낸다.
- 제1항에 있어서, R2가 모르폴리노, 티오모르폴리노 또는 티오모르폴리노, S,S-디옥사이드 라디칼을 나타내는 치환된 시클로프로필아미노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
- 제1항에 있어서, 2-시클로프로필아미노-4-모르폴리노-6-n-프로필-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
- 제1항에 있어서, 2-시클로프로필-4-시클로프로필아미노-6-모르폴리노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
- 제1항에 있어서, 2-시클로부틸-4-시클로프로필아미노-6-모르폴리노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
- 제1항에 있어서, 2-시클로부틸-4-시클로프로필아미노-6-티오모르폴리노-1,3,5-트리아진 또는 이것의 비독성의 약학적으로 허용되는 산 부가염.
- 제1항에 있어서, 2-시클로부틸-4-시클로프로필아미노-6-티오모르폴리노-1,3,5-트리아진 S,S-디옥사이드 또는 이것의 비독성의 약학적으로 하용되는 산 부가염.
- 하기식(II)의 클로로-시클로프로필아미노-1,3,5-트리아진을 식 R2H(III)아민과 반응시키는 것으로 이루어지는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.(상기 식에서, R1및 R2는 제1항에서 정의된 것과 같다.)
- 하기식(IV)의 클로로-1,3,5-트리아진을 식의 시클로프로필아민과 반응시키는 것으로 이루어지는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.
- 하기식(VI)의 N-시클로프로필비구아니드를 식 R1-COO Alk(VII)의 알킬에스테르와 반응시키는 것으로 이루어지는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.(상기 식에서, R1및 R2는 제1항에서 정의된 것과 같고, Alk는 1 내지 4탄소원자를 가지는 알킬 라디칼을 나타낸다.)
- 하기식(I)의 시클로프로필아미노-1,3,5-트리아진을 산화시키는 것으로 이루어지는, R2가 티오모르폴리노 S-옥사이드, 티오모르폴리노 S,S-디옥사이드, 3-티아졸리디닐 S-옥사이드 또는 3-티아졸리디닐 S,S-디옥사이드 라디칼을 나타내는, 식(I)의 치환된 시클로프로필아미노-1,3,5-트리아진의 제조 방법.(상기 식에서, R1은 제1항에서 정의된 것과 같고, R2는 티오모르폴리노 또는 3-티아졸리디닐 라디칼을 나타낸다.)
- 제1항에서 청구되는 시클로프로필아미노-1,3,5-트리아진의 치료적 유효량과 그것의 약학적으로 허용된 고체 또는 액체 희석제 또는 담체를 포함하는 약학 조성물.
- 알츠하이머병, 노인성 치매, 알츠하이머 타입과 관련되고 진화성인지 병리학과 관련된 장애를 가지는 환자의 치료방법으로서, 상기 환자에 제1항에 청구된 치환된 시클로프로필아미노-1,3,5-트리아진의 유효량을 투여하는 것으로 이루어지는 방법.
- 불안, 우울 및 기분장애 환자의 치료방법으로서, 상기 환자에 제1항에 청구된 치환된 시클로프로필아미노-1,3,5-트리아진의 유효량을 투여하는 것으로 이루어지는 방법.
- 염증현상 및 천식 환자의 치료방법으로서, 상기 환자에 제1항에 청구된 치환된 시클로프로필아미노-1,3,5-트리아진의 유효량을 투여하는 것으로 이루어지는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919116039A GB9116039D0 (en) | 1991-07-25 | 1991-07-25 | Substituted cyclopropylamino-1,3,5-triazines |
GB9116039.0 | 1991-07-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR930002327A true KR930002327A (ko) | 1993-02-23 |
KR100221400B1 KR100221400B1 (ko) | 1999-09-15 |
Family
ID=10698941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920013231A KR100221400B1 (ko) | 1991-07-25 | 1992-07-24 | 치환된 시클로프로필아미노-1,3,5-트리아진 |
Country Status (21)
Country | Link |
---|---|
US (2) | US5258513A (ko) |
EP (1) | EP0527117B1 (ko) |
JP (1) | JP3138540B2 (ko) |
KR (1) | KR100221400B1 (ko) |
AT (1) | ATE159719T1 (ko) |
AU (1) | AU648424B2 (ko) |
CA (1) | CA2072680A1 (ko) |
DE (1) | DE69222903T2 (ko) |
DK (1) | DK0527117T3 (ko) |
ES (1) | ES2109332T3 (ko) |
FI (1) | FI923314A (ko) |
GB (1) | GB9116039D0 (ko) |
GR (1) | GR3026017T3 (ko) |
HU (1) | HU218207B (ko) |
IE (1) | IE922422A1 (ko) |
NO (1) | NO300683B1 (ko) |
NZ (1) | NZ243681A (ko) |
PL (2) | PL169646B1 (ko) |
RU (1) | RU2095353C1 (ko) |
UA (1) | UA27749C2 (ko) |
ZA (1) | ZA924920B (ko) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
US5488056A (en) * | 1994-10-31 | 1996-01-30 | Eli Lilly And Company | Method for treating anxiety |
US6400819B1 (en) * | 1996-03-28 | 2002-06-04 | Hitachi, Ltd. | Method and apparatus for executing communication in real-time and data structure for real-time data communication |
WO1998011076A1 (de) * | 1996-09-13 | 1998-03-19 | Lonza Ag | Verfahren zur herstellung von 6-methyl-2-methylamino-4-methoxy-1,3,5-triazin |
US6538750B1 (en) | 1998-05-22 | 2003-03-25 | Cyberoptics Corporation | Rotary sensor system with a single detector |
US6292261B1 (en) | 1998-05-22 | 2001-09-18 | Cyberoptics Corporation | Rotary sensor system with at least two detectors |
FI105684B (fi) * | 1998-08-21 | 2000-09-29 | Neste Chemicals Oy | Enantioselektiiviset kiraaliset sulfidikatalyytit, menetelmä niiden valmistamiseksi ja niiden käyttö stereoselektiivisiin epoksidointi-, syklopropanointi- ja atsiridinointireaktioihin |
AU781849C (en) * | 1999-06-17 | 2006-03-02 | Synta Pharmaceuticals Corp. | Inhibitors of IL-12 production |
US6384032B1 (en) * | 1999-06-17 | 2002-05-07 | Shionogi Bioresearch Corp. | Inhibitors of IL-12 production |
MXPA02001830A (es) | 1999-08-21 | 2002-08-12 | Byk Gulden Lomberg Chem Fab | Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor. |
CN1098876C (zh) * | 1999-09-21 | 2003-01-15 | 上海赛璐化工股份有限公司 | 一种长碳链共聚酰胺及其制备方法 |
US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
US6680315B2 (en) * | 2000-06-15 | 2004-01-20 | Synta Pharmaceuticals Corp. | Triazine compounds |
US7323462B2 (en) * | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EA200501548A1 (ru) | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | Ингибиторы фосфодиэстераз при бесплодии |
TWI359017B (en) * | 2003-11-10 | 2012-03-01 | Synta Pharmaceuticals Corp | Heteroaryl-hydrazone compounds |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
ES2664873T3 (es) | 2011-03-01 | 2018-04-23 | Synergy Pharmaceuticals Inc. | Proceso de preparación de agonistas de guanilato ciclasa C |
WO2013022279A2 (en) * | 2011-08-08 | 2013-02-14 | Hanall Biopharma Co., Ltd. | N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160831A (en) * | 1976-08-19 | 1979-07-10 | Ciba-Geigy Corporation | Novel insecticides |
DE2963654D1 (en) * | 1978-02-03 | 1982-11-04 | Ciba Geigy Ag | 2-methylthio-4-cyclopropylamino-6-(alpha,beta-dimethylpropylamino)-s-triazine and the use of triazine derivatives as seewater algicides |
GB8819493D0 (en) * | 1988-08-16 | 1988-09-21 | Ucb Sa | 2-amino-4-morpholino-6-propyl-1 3 5-triazines |
GB8819494D0 (en) * | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
-
1991
- 1991-07-25 GB GB919116039A patent/GB9116039D0/en active Pending
-
1992
- 1992-06-29 CA CA002072680A patent/CA2072680A1/en not_active Abandoned
- 1992-07-02 ZA ZA924920A patent/ZA924920B/xx unknown
- 1992-07-09 ES ES92870101T patent/ES2109332T3/es not_active Expired - Lifetime
- 1992-07-09 EP EP92870101A patent/EP0527117B1/fr not_active Expired - Lifetime
- 1992-07-09 DK DK92870101.0T patent/DK0527117T3/da active
- 1992-07-09 AT AT92870101T patent/ATE159719T1/de not_active IP Right Cessation
- 1992-07-09 DE DE69222903T patent/DE69222903T2/de not_active Expired - Fee Related
- 1992-07-20 US US07/914,583 patent/US5258513A/en not_active Expired - Fee Related
- 1992-07-21 FI FI923314A patent/FI923314A/fi unknown
- 1992-07-23 NO NO922922A patent/NO300683B1/no not_active IP Right Cessation
- 1992-07-23 NZ NZ243681A patent/NZ243681A/en unknown
- 1992-07-23 AU AU20534/92A patent/AU648424B2/en not_active Ceased
- 1992-07-24 RU SU925052292A patent/RU2095353C1/ru active
- 1992-07-24 IE IE242292A patent/IE922422A1/en not_active Application Discontinuation
- 1992-07-24 KR KR1019920013231A patent/KR100221400B1/ko not_active IP Right Cessation
- 1992-07-24 PL PL92311241A patent/PL169646B1/pl unknown
- 1992-07-24 HU HU9202441A patent/HU218207B/hu not_active IP Right Cessation
- 1992-07-24 JP JP04198702A patent/JP3138540B2/ja not_active Expired - Fee Related
- 1992-07-24 PL PL92295403A patent/PL169247B1/pl unknown
-
1993
- 1993-06-18 UA UA93003144A patent/UA27749C2/uk unknown
- 1993-08-09 US US08/103,119 patent/US5348956A/en not_active Expired - Fee Related
-
1998
- 1998-01-28 GR GR980400187T patent/GR3026017T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ZA924920B (en) | 1993-04-28 |
DE69222903D1 (de) | 1997-12-04 |
PL169247B1 (pl) | 1996-06-28 |
HU9202441D0 (en) | 1992-10-28 |
NO922922L (no) | 1993-01-26 |
RU2095353C1 (ru) | 1997-11-10 |
JP3138540B2 (ja) | 2001-02-26 |
ES2109332T3 (es) | 1998-01-16 |
AU2053492A (en) | 1993-01-28 |
HUT66218A (en) | 1994-10-28 |
FI923314A0 (fi) | 1992-07-21 |
HU218207B (hu) | 2000-06-28 |
ATE159719T1 (de) | 1997-11-15 |
UA27749C2 (uk) | 2000-10-16 |
DE69222903T2 (de) | 1998-03-26 |
IE922422A1 (en) | 1993-01-27 |
NO922922D0 (no) | 1992-07-23 |
US5258513A (en) | 1993-11-02 |
DK0527117T3 (da) | 1998-05-18 |
NZ243681A (en) | 1997-06-24 |
EP0527117A1 (fr) | 1993-02-10 |
AU648424B2 (en) | 1994-04-21 |
CA2072680A1 (en) | 1993-01-26 |
KR100221400B1 (ko) | 1999-09-15 |
GR3026017T3 (en) | 1998-04-30 |
US5348956A (en) | 1994-09-20 |
GB9116039D0 (en) | 1991-09-11 |
FI923314A (fi) | 1993-01-26 |
EP0527117B1 (fr) | 1997-10-29 |
NO300683B1 (no) | 1997-07-07 |
JPH06220026A (ja) | 1994-08-09 |
PL295403A1 (ko) | 1993-02-08 |
PL169646B1 (pl) | 1996-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930002327A (ko) | 치환된 시클로프로필아미노-1, 3, 5-트리아진 | |
HUT61742A (en) | Process for producing cyclic amide derivatives and pharmaceutical compositions comprising same | |
ZA932168B (en) | Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them | |
ATE143943T1 (de) | Arylglycinamidderivate, verfahren zur deren herstellung und deren verwendung zur therapie der dysurie | |
GR3030798T3 (en) | 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors. | |
FI903819A0 (fi) | 1,3-dihydro-1-(pyridinylamino)-2h-indol- 2-oner, foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel. | |
NZ226415A (en) | Spiro-oxathiolane/quinuclidine derivatives and pharmaceutical compositions | |
HUT54156A (en) | Process for producing new n-heteroarylpurine-6-amine derivatives and pharmaceutical compositions comprising such compounds | |
HU908014D0 (en) | Process for producing amino-carbonyl-carbamates analogues to physostigmine and pharmaceutical preparatives containing these compounds | |
DE69500274T2 (de) | Thiazin- oder Thiomorpholinderivate | |
DK0573318T3 (da) | 4-phenylcarbamoyl-3-isoxazolcarboxylsyreforbindelser, fremgangsmåde til deres fremstilling, farmaceutiske præparater med in | |
FI103887B (fi) | Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi | |
HUT61755A (en) | Process for producing 3-(1,2-benzisoxazol-3-yl)-4-pyridineamines and their derivatives | |
ATE123776T1 (de) | Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen. | |
DE69112785D1 (de) | Phthalidylidenderivate von Carnitin und Alkanoylcarnitinen sowie diese enthaltende pharmazeutische Mittel. | |
GR3021200T3 (en) | (Cyclohexyl)-alken compounds, process for their preparation and pharmaceutical compositions containing them. | |
DE69025274D1 (de) | Hexahydro-1H-chino[4,3,2-ef][1,4]benzoxazepine und verwandte Verbindungen und Zwischenprodukte zur Herstellung und Verwendung als Arzneimittel | |
GR3019469T3 (en) | 2-(3-Phenylpropyl)hydrazines, intermediates in and a process for the preparation thereof, and their use as medicaments | |
HU912675D0 (en) | Process for producing derivatives of carbamoil-1-(pyridinyl-alkyl)-1h-indole and -indole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |